Bristol-Myers Squibb Company
Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group

Last updated:

Abstract:

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

28 Jul 2016

Issue date:

9 Jun 2020